Product Description
SYS6011 is a monoclonal antibody drug that binds to specific receptors on the surface of tumor cells and immune cells infiltrated by tumors to achieve the effect of killing tumor cells by removing immune suppression in the tumor microenvironment. The product was declared as a class 1 biological product for treatment, and the approved clinical indication is solid tumors. Preclinical studies have shown that SYS6011 has shown good anti-tumor effects on various cancers, and has the potential to show good treatment results in subsequent clinical trials. This product has filed a number of patent applications at home and abroad. (Sourced from: https://news.futunn.com/en/post/33716215/shiyao-pharmaceutical-group-01093-monoclonal-antibody-drug-sys6011-approved-for?level=1&data_ticket=1718216802760346)
Mechanisms of Action: CD73 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CSPC Pharmaceutical Group Jushi Biopharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20242014 | P1 |
Unknown |
Oncology Solid Tumor Unspecified |
None |